Dixon Mitchell Investment Counsel Inc. Pfizer Inc Transaction History

Dixon Mitchell Investment Counsel Inc.

$2.2 Trillion
Q3 2024

39 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 18, 2024	BUY	$25.89 - $29.73 $17,087 - $19,621	660 New	660 $18.3 Million
Q2 2020 Jan 17, 2024	SELL	$30.12 - $36.54 $197,014 - $239,008	-6,541 Closed	0 $0
Q1 2020 Jan 17, 2024	SELL	$27.03 - $38.62 $57,195 - $81,719	-2,116 Reduced 24.44%	6,541 $213 Million
Q4 2019 Jan 17, 2024	SELL	$32.92 - $37.36 $31,043 - $35,230	-943 Reduced 9.82%	8,657 $339 Million
Q3 2019 Jan 17, 2024	SELL	$32.49 - $42.13 $31,222 - $40,486	-961 Reduced 9.1%	9,600 $345 Million
Q2 2019 Jan 17, 2024	SELL	$36.98 - $41.52 $142,890 - $160,433	-3,864 Reduced 26.79%	10,561 $458 Million
Q1 2019 Jan 17, 2024	SELL	$37.5 - $41.2 $35,437 - $38,934	-945 Reduced 6.15%	14,425 $613 Million
Q4 2018 Jan 17, 2024	SELL	$38.47 - $43.86 $29,121 - $33,202	-757 Reduced 4.69%	15,370 $671 Million
Q3 2018 Jan 17, 2024	SELL	$34.47 - $41.81 $81,452 - $98,797	-2,363 Reduced 12.78%	16,127 $711 Million
Q2 2018 Jan 17, 2024	SELL	$32.98 - $35.16 $33,903 - $36,144	-1,028 Reduced 5.27%	18,490 $671 Million
Q1 2018 Jan 17, 2024	BUY	$31.91 - $37.02 $6,509 - $7,552	204 Added 1.06%	19,518 $693 Million
Q4 2017 Jan 17, 2024	SELL	$33.26 - $35.29 $27,672 - $29,361	-832 Reduced 4.13%	19,314 $700 Million
Q3 2017 Jan 17, 2024	BUY	$31.0 - $34.15 $13,237 - $14,582	427 Added 2.17%	20,146 $719 Million
Q2 2017 Jan 17, 2024	SELL	N/A	-1,920 Reduced 8.87%	19,719 $662 Million
Q1 2017 Jan 17, 2024	SELL	N/A	-16,726 Reduced 43.6%	21,639 $740 Million
Q4 2016 Jan 17, 2024	SELL	N/A	-2,130 Reduced 5.26%	38,365 $1.25 Billion
Q3 2016 Jan 17, 2024	SELL	N/A	-2,305 Reduced 5.39%	40,495 $1.37 Billion
Q2 2016 Jan 17, 2024	SELL	N/A	-1,146 Reduced 2.61%	42,800 $1.51 Billion
Q1 2016 Jan 17, 2024	SELL	N/A	-809 Reduced 1.81%	43,946 $1.3 Billion
Q4 2015 Jan 17, 2024	SELL	N/A	-4,675 Reduced 9.46%	44,755 $1.44 Billion
Q3 2015 Jan 17, 2024	BUY	N/A	9,132 Added 22.66%	49,430 $1.55 Billion
Q2 2015 Jan 17, 2024	SELL	N/A	-282 Reduced 0.69%	40,298 $1.35 Billion
Q1 2015 Jan 17, 2024	SELL	N/A	-9,090 Reduced 18.3%	40,580 $1.41 Billion
Q3 2014 Jan 17, 2024	SELL	N/A	-110 Reduced 0.22%	49,670 $1.47 Billion
Q2 2014 Jan 17, 2024	SELL	N/A	-1,380 Reduced 2.7%	49,780 $1.48 Billion
Q1 2014 Jan 17, 2024	BUY	N/A	1,300 Added 2.61%	51,160 $1.64 Billion
Q4 2013 Jan 17, 2024	BUY	N/A	1,980 Added 4.14%	49,860 $1.53 Billion
Q3 2013 Jan 17, 2024	SELL	N/A	-1,130 Reduced 2.31%	47,880 $1.38 Billion
Q2 2013 Jan 17, 2024	SELL	N/A	-1,590 Reduced 3.14%	49,010 $1.37 Billion
Q1 2013 Jan 17, 2024	BUY	N/A	8,060 Added 18.95%	50,600 $1.46 Billion
Q4 2012 Jan 17, 2024	BUY	N/A	4,150 Added 10.81%	42,540 $1.07 Billion
Q3 2012 Jan 17, 2024	BUY	N/A	2,020 Added 5.55%	38,390 $954 Million
Q2 2012 Jan 17, 2024	BUY	N/A	5,570 Added 18.08%	36,370 $837 Million
Q1 2012 Jan 17, 2024	BUY	N/A	30,800 New	30,800 $697 Million
Q4 2007 Jan 17, 2024	SELL	N/A	-3,153 Reduced 0.94%	331,434 $7.53 Billion
Q3 2007 Jan 17, 2024	BUY	N/A	43,202 Added 14.83%	334,587 $8.17 Billion
Q2 2007 Jan 17, 2024	BUY	N/A	15,502 Added 5.62%	291,385 $7.45 Billion
Q1 2007 Jan 17, 2024	BUY	N/A	42,700 Added 18.31%	275,883 $6.97 Billion
Q4 2006 Jan 17, 2024	BUY	N/A	233,183	233,183 $6.04 Billion

Others Institutions Holding PFE

# of Institutions

3,271

Shares Held

3.63B

Call Options Held

74.3M

Put Options Held

107M

Vanguard Group Inc Valley Forge, PA

516M
Shares

$13.8 Billion
0.27% of portfolio
Black Rock Inc. New York, NY

424M
Shares

$11.3 Billion
0.27% of portfolio
State Street Corp Boston, MA

287M
Shares

$7.67 Billion
0.36% of portfolio
Wellington Management Group LLP Boston, MA

166M
Shares

$4.44 Billion
0.85% of portfolio
Charles Schwab Investment Management Inc San Francisco, CA

130M
Shares

$3.48 Billion
0.73% of portfolio

View Full List

About PFIZER INC

Ticker PFE
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 5,612,349,952
Market Cap $150B
Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...

More about PFE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dixon Mitchell Investment Counsel Inc., based on Form 13F filings with the SEC.

News

Stay updated on Dixon Mitchell Investment Counsel Inc. with notifications on news.

Account